Neurometrix Inc (NURO) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $4.50. Rodman & Renshaw advised their investors in a research report released on Jun 28, 2016.
Neurometrix Inc (NURO) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.7 and reached the intraday high at $1.79. The bulls started the profit booking and pushed the shares to intraday low of $1.7. The trading session was marked by a volume range of 2,48,228 shares exchanging hands. The 52-week high of the shares is $4.96 and the 52-week low is $1.35. The market cap of the company stands at $7.6 M and there are 43,89,899 shares in public circulation.
In a different news, on Jun 1, 2016, Shai Gozani (CEO) purchased 2,500 shares at $1.71 per share price. According to the SEC, on May 23, 2016, Francis X Mcgillin (Senior VP, Consumer) purchased 1,000 shares at $1.65 per share price. On May 19, 2016, Thomas T Higgins (CFO) purchased 3,200 shares at $1.54 per share price, according to the Form-4 filing with the securities and exchange commission.
NeuroMetrix Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain nerve diseases and sleep disorders. The Company is engaged in product development manufacturing regulatory affairs and compliance sales and marketing and customer support. The Company sells medical devices and after-market consumable products and accessories. The Company has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. The Company’s products include Quell SENSUS DPNCheck and ADVANCE System.